actoferrin in the treatment of Long COVID

Completed

Conditions: Long-COVID
10047438

Registration Number: NL-OMON50577

Lead Sponsor: ongziekten

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 72

Inclusion Criteria

- Subjects aged 18-70 years with proven COVID-19 (positive COVID-19
RT-PCR- or antibody test)
- Persistent or newly developed long COVID symptoms at least 12 weeks
post-primary SARS-CoV-2 infection
- Patients with a positive COVID-19 RT-PCR- or antibody test not older than 9
months

Exclusion Criteria

- Patients admitted to the ICU (COVID-19-related)
- COVID-19-related cardiac or pulmonary tissue damage
- Acute infection or current systemic immunological disorders
- Oral and/or inhaled use of corticosteroids or use of other immune-modulatory
medication
- Current psychiatric disorders
- Communication difficulties
- Pregnant or lactating women
- Age >70 years
- Patients with milk allergy or a known or suspected allergy or any
contraindications to lactoferrin or microcrystalline cellulose (lactoferrin can
be used by individuals with lactose intolerance)

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Primary endpoint: Fatigue symptoms (measured with FAS) within 6 weeks and 3<br /><br>months after initiation of intervention.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary endpoints: Cognitive function (CFQ), Anxiety and depression (HADS),<br /><br>Inflammatory parameters in blood (e.g. IL-6, hsCRP) and muscle strength<br /><br>(Handgrip strength and 30sec Sit-to-Stand test).</p><br>